Xeris Biopharma delivered the kind of quarter that changes a company's growth narrative. The company earned $0.06 per share, well ahead of the $0.02 consensus for a 200.0% surprise. Revenue of $107.23 million beat the $100.97 million estimate by 6.2% and grew 44.2% year over year. The bigger news was what management did with that momentum. It raised full-year 2026 revenue guidance to $395-$405 million and lifted its 2030 total revenue outlook to more than $1 billion, up from roughly $750 million. The central takeaway is that Recorlev's expanded salesforce has moved, in management's words, "from build to yield." Reported growth now reflects that shift rather than relying on promises of it.
The quality of the beat holds up better than most small-cap biotech upside. Revenue growth reaccelerated sharply to 44%, after 29% in the second quarter and 38% in the first. Sequentially, revenue rose 16%. Recorlev did the heavy lifting. Its net revenue reached $71.5 million, up 93% year over year and 26% sequentially from $56.8 million in Q2. Favorable mix pushed gross margin to 88%, from 86% in Q2 and 85% a year ago. Adjusted EBITDA climbed to $30.8 million, from $19.3 million in Q2 and $15.1 million in Q1. GAAP net income was $11.3 million versus $0.6 million a year earlier, a swing from breakeven to genuine profitability. The comparison was also clean. Xeris retired its remaining 8% 2028 convertible notes in July, removing about $34 million of debt and roughly $3 million of annual interest, with no related charges in the quarter. That retirement partly involved stock: basic weighted shares rose to 180.9 million from 163.6 million a year ago, so per-share leverage is being diluted somewhat.
The call reinforced that this is an enterprise-wide improvement, not a single-product spike. Management said Recorlev rep productivity is now running ahead of expectations, compared with merely tracking in line at Q2. Referrals and new patient starts hit records. Keveyis grew 9% for its fourth straight year-over-year gain, and a new patent is expected to protect it through at least 2043. Gvoke was the blemish. Net revenue fell 14% year over year to $21.7 million because of a one-time $4 million Medicaid gross-to-net adjustment. Underlying prescription demand, however, rose 20% sequentially and 5% year over year on a stronger-than-usual back-to-school season. The guidance pattern also matters. The three previous raises only lifted the low end of the range. This time the top end moved meaningfully, from $390 million to $405 million. Against $282.5 million in nine-month revenue, the new range implies fourth-quarter revenue of roughly $112-$123 million, extending the sequential climb.
Bears still have legitimate ammunition, mostly on cost and access. Management raised its SG&A growth outlook for a third time this year, to about $60 million, up from $45 million and then $50 million. Q3 SG&A alone was $64.1 million. The R&D growth outlook was cut to about $15 million from $25 million, but management attributed that to the timing of XP-8121 spending rather than reduced scope. That pushes cost into 2027 instead of saving it. Recorlev access remains prior-authorization intensive, and ANDA patent litigation is ongoing. The $1 billion 2030 target also leans heavily on Recorlev; management now sees the drug approaching $1 billion three to four years sooner than its prior 2035 target. XP-8121 adds a longer-dated option. Its pivotal Cornerstone trial is on track to start by year-end, with topline data in late 2028 and potential launch in 2030. Updated diabetes-society guidance recommending hypercortisolism screening in difficult-to-control type 2 diabetes is a plausible tailwind for Recorlev diagnosis rates.
The market setup is more complicated than the surprise implies, because investors front-ran much of this story. Shares rose 45.5% from the $7.19 open after the August report to $10.46 heading into this release. That leaves them about 39% above the 200-day moving average and only 8.4% below the 52-week high of $11.42 set on October 19. Investor sentiment moved from mildly negative at -0.14 to modestly positive at 0.23, a meaningful shift in tone but well short of euphoric. The Earnings Whispers trend signals are largely positive, with price, sequential growth, momentum and AVWAP readings all pointing the same way. Even so, the stock entered the report near the upper end of its inter-earnings range, so a strong quarter was at least partly expected.
The bottom line is that Xeris turned a credible commercial-expansion thesis into reported acceleration. Revenue growth sped up, margins and EBITDA stepped higher, guidance rose at the top end, and the long-range outlook increased by about a third. The open questions are whether repeated SG&A raises and deferred R&D spending will dilute the operating leverage. Investors will also be watching whether Recorlev's access hurdles cap the trajectory. With the stock already up sharply since August, the next leg depends on continued Recorlev execution rather than on the market recognizing this quarter's beat.